News and Trends 31 Mar 2016
Money Magnet Immunocore kicks off Trial for Eye Melanoma
Immunocore (UK) has enrolled its first patient for a phase I trial that will test its ImmTAC as a standalone therapy for uveal melanoma, the most common eye cancer. Immunocore is famous for having raised the biggest European Private round ever (€300M), and so it’s no wonder that if often makes our tops here at […]